¿Puede ser donante de órganos un paciente con enfermedad de pompe?

Nefrologia

Volumn 34, Issue 3, 2014, Pages 415-416

  Morales Ruiz, Enrique ^a   Gutiérrez Martínez, Eduardo ^a   Cordero, Carolina ^a   González Monte, Esther ^a   Hernández Martínez, Eduardo ^a   Praga Terente, Manuel ^a   Andrés Belmonte, Amado ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DONOR; DONOR SELECTION; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN;

DONOR SELECTION; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; TISSUE DONORS;

EID: 84901439038     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2014.Feb.12456     Document Type: Letter

References (5)

1. Barba-Romero MA, Barrot E, Bautista-Lorite J, Gutierrez-Rivas E, Illa I, Jimenez LM, et al. Clinical guidelines for late-onset Pompe disease. Rev Neurol 2012;54(8):497-507.
2. Cupler EJ, Berger KI, Leshner RT, Wolfe GI, Han JJ, Barohn RJ, et al. AANEM Consensus Committee on Late-onset Pompe Disease. Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve 2012;45(3):319-33.
3. Filosto M, Todeschini A, Cotelli MS, Vielmi V, Rinaldi F, Rota S, et al. Non-muscle involvement in late-onset glycogenosis II. Acta Myol 2013;32(2):91-4.
4. Oktenli C. Renal magnesium wasting, hypomagnesemic, hypocalcemia, hypocalciuria and osteopenia in a patient with glycogenosis type II. Am J Nephrol 2000;20:412-7.
5. Hunley TE, Corzo D, Dudek M, Kishnani P, Amalfitano A, Chen YT, et al. Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease. Pediatrics 2004;114(4):e532-5.